Oncologie

Taxol ® (paclitaxel) 225mg/m2 by 3-hour infusion without G-CSF as a first line therapy in patients with Metastatic Breast Cancer

Proceedings of the American Society of Clinical Oncology 1996 Bonneterre J, Tubiana-Hulin M, Chollet Ph, Chevallier B, Fumoleau P, Kerbrat P, Vié B, Khayat D, Tubiana N, Lejeune C, Soler-Michel P, Soares JA, Pellae-Cosset B, Chazard M.

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Use of Digital Health Technology to Enable Drug Development
Oncologie

Use of Digital Health Technology to Enable Drug Development

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study 
Oncologie

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study 

Primary efficacy analysis of a phase II study of neoadjuvant Bevacizumab, chemotherapy, and Trastuzumab in HER2-positive inflammatory breast cancer: BEVERLY 2 study
Oncologie

Primary efficacy analysis of a phase II study of neoadjuvant Bevacizumab, chemotherapy, and Trastuzumab in HER2-positive inflammatory breast cancer: BEVERLY 2 study